Plasma cell myeloma
Not yet recruitingReduced vs Standard Dose Belantamab Mafodotin with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: A Phase II MRD‑Guided Study
Reduced vs Standard Dose Belantamab Mafodotin with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: A Phase II MRD‑Guided Study
- Disease:Plasma cell myeloma
- Substances:Belantamab MafodotinPomalidomide
Poland- Participants:18–64 years · 65+ years
- Substances:Belantamab Mafodotin
- Sponsor:Polish Myeloma Consortium











